ABSTRACT
In this short report, we bring some data-driven analyses of COVID-19 mortality in Brazil. The impact of COVID-19 is evaluated by comparing the 2019 and 2020 civilian death records. There is evidence of a considerable excess of deaths since the pandemic started with respect to the previous year. In some states, it is clear that not all excess of deaths in 2020 is due to COVID-19, but to other respiratory causes that did not present the same prevalence in the previous year. Because of this unusual behavior of respiratory deaths, we may infer the evidence of a huge amount of under-reporting deaths due to the COVID-19. The data also shows that COVID-19 has produced an excess death in all ages besides people above 90 and below 10 years. In addition, when separates by sex, data indicate a larger increase in the deaths among males than females.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This is a statistical study using a dataset from a public database concerning the COVID-19 mortality in Brazil.
Funding Statement
The authors thank the financial support from the Brazilian agencies National Council for Scientific and Technological Development (CNPq), Coordination for the Improvement of Higher Education Personnel)(CAPES), and the Carlos Chagas Filho Research Foundation of Rio de Janeiro State (FAPERJ).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This is a statistical study using anonymous data from a public database, so no approval from an ethics committee was necessary.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
1
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
1
Blogs/Media
Author Videos